Modern has put plans to build a vaccine plant in Kenya on hold, a sign its move to invest in pandemic preparedness in Africa has dropped the agenda as COVID-19 sales decline, Oliver Barnes, Andres Schipani, and Michael Peel of The Financial Times says. A year ago, Modern made a deal with the Kenyan government to invest $200M in a facility that would produce up to 500M vaccine shots a year. It has yet to buy a plot earmarked for it in a special economic zone near Nairobi, two people familiar with the matter said. In a recent statement to the Financial Times, the company confirmed it had “paused its efforts.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s (NASDAQ:MRNA) Latest Cancer Treatment Gives Shares New Life
- Early notable gainers among liquid option names on April 9th
- Moderna Stock (NASDAQ:MRNA): This mRNA Tech Pioneer Has Rebound Potential
- Arbutus ‘pleased’ with claim construction ruling in patent infringement suit
- Moderna could owe $1B-$3B in royalties, says Jefferies